GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » Degree of Operating Leverage

SLNO (Soleno Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Soleno Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Soleno Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Soleno Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Degree of Operating Leverage Chart

Soleno Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soleno Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Soleno Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Soleno Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soleno Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Soleno Therapeutics's Degree of Operating Leverage falls into.


;
;

Soleno Therapeutics Degree of Operating Leverage Calculation

Soleno Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -194.957 (Mar. 2025) / -52.216 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=2.7337/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Soleno Therapeutics  (NAS:SLNO) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Soleno Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics Business Description

Traded in Other Exchanges
Address
100 Marine Parkway, Suite 400, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Executives
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505